Dr. McDreamy has signed onto yet another cancer awareness initiative. | Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with ...
FDA’s CRLs reveal critical errors in AstraZeneca’s Saphnelo data, efficacy doubts for GSK’s Exdensur
In a scathing rebuke (PDF) to AstraZeneca, the FDA cited “critical data quality issues that affect key analyses, including the primary endpoint” within a dataset for Saphnelo (anifrolumab) for the ...
Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a re-examination of the decision from the regulator's Committee for Medicinal | ...
With a vital obesity launch now underway in the U.S., Novo Nordisk is casting its attention eastward as it shores up the prospects of its Wegovy pill in Europe and beyond. | Novo will invest 432 ...
Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential ...
With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based ...
Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...
Following an extensive Middle East military build-up by the U.S. in recent weeks, the U.S. and Israel on Feb. 28 launched attacks across Iran. In response, Iran launched retaliatory attacks on Israel, ...
Ahead of a rescheduled meeting of the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), Department of Health and Human Services (HHS) Secretary | ...
As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.
Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...
Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs that it says are often overlooked by bigger contract manufacturers, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results